Success in the rare disease sector in 2025 requires more than just clinical excellence; it requires a deep understanding of the patient journey and the complex regulatory pathways that govern global medicine. Business leaders are increasingly looking at "long-term value creation" rather than short-term profits, recognizing that a therapy that works is only valuable if it can be successfully...